<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952392</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CFR-BRI-2012/1</org_study_id>
    <nct_id>NCT01952392</nct_id>
  </id_info>
  <brief_title>Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome</brief_title>
  <acronym>AReMIS</acronym>
  <official_title>Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk
      of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a
      history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using
      ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where
      aspirin is considered a covariate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Medical information</measure>
    <time_frame>At baseline visit</time_frame>
    <description>History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Current</time_frame>
    <description>Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Recent</time_frame>
    <description>Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Past</time_frame>
    <description>Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other medical events of interest</measure>
    <time_frame>During follow-up (up to 12 months)</time_frame>
    <description>rMI, stroke, bleeding, death</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4992</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <description>Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 years or more, both genders,with an acute coronary syndrome, agreed to
        participate and able to respond to an interview in French and/or providing the details of
        an alternative replier (proxy) if necessary.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed
        to participate and able to respond to an interview in French and/or providing the details
        of an alternative replier (proxy) if necessary.

        No Exclusion Criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1819&amp;filename=CSR_Synopsis_AReMIS.pdf</url>
    <description>CSR_Synopsis</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effectiveness study</keyword>
  <keyword>Acute coronary Syndrome</keyword>
  <keyword>Real-life</keyword>
  <keyword>France</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

